Associação de níveis plasmáticos de PAI-1 e polimorfismo 4G/5G em pacientes com doença arterial coronariana

Lima, Luciana Moreira; Carvalho, Maria das Graças; Neto, Cirilo P. Fonseca; Garcia, José Carlos Faria; Sousa, Marinez O.

doi:10.1590/s0066-782x2011005000110

Cited by 15 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this finding conflicts with the results of our research; the discrepancy could be due to differences in the ethnic group or sample size used. On the other hand, the Turkish postmenopausal women exhibited only osteoporosis [35], whereas our study participants exhibited symptoms of greater severity, such as compound fracture due to osteoporosis; this could also be the reason for the discrepancy between the results of the two studies. There are several limitations to our study.…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women

Kim

Han

Lee

et al. 2016

IJMS

View full text Add to dashboard Cite

Osteoporosis and osteoporotic fractures are strongly associated with mortality and morbidity, both in developing and developed countries. Menopause accelerates bone loss due to estrogen deficiency and age-related linear bone loss. We investigated plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in postmenopausal women with osteoporotic vertebral compression fractures (OVCFs). In this case-control study, 355 postmenopausal women were genotyped for the presence of PAI-1 gene polymorphisms −844A > G, −675 4G > 5G, 43G > A, 9785A > G, and 11053T > G. Genetic polymorphisms of PAI-1 were analyzed by the polymerization chain reaction restriction fragment length polymorphism assay, and their association with disease status and folate and homocysteine levels was determined in 158 OVCF patients and 197 control subjects. The PAI-1 −675 5G5G (adjusted odds ratio (AOR), 3.302; p = 0.017) and 43GA + AA (AOR, 2.087; p = 0.042) genotype frequencies showed significant association with the increased prevalence of OVCFs in postmenopausal women. In addition, we performed gene–environment interaction studies and demonstrated an association between PAI-1 gene polymorphisms and OVCF prevalence. Our novel finding is the identification of several PAI-1 genetic variants that increase susceptibility to OVCF. Our findings suggest that polymorphisms in PAI-1 may contribute to OVCF, and that they can be developed as biomarkers for evaluating OVCF risk.

show abstract

Section: Discussionmentioning

confidence: 65%

“…First, serum PAI-1 concentrations were not examined in our study population. Previous studies have evaluated the contribution of each PAI-1 polymorphism to serum PAI-1 expression [35,36,37]. Second, functional studies for PAI-1 SNP were not performed to elucidate OVCF-related pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women

Kim

Han

Lee

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…As indicated in some previous studies, 4G/4G genotype or 4G allele may be a risk factor for development of disease,[121314] whereas others proposed a protective role for 4G/4G genotype or 4G allele against symptoms. [151617] Also, in our previous study we showed that FMF patients carrying 5G/5G genotype are more susceptible to the progression of disease symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…The association of PAI-1 gene polymorphism with several diseases such as Familial Mediterranean Fever,[11] Type 2 Diabetes,[12] Acute Myocardial Infarction,[13] and Coronary Artery Disease[14] has been investigated. As indicated in some previous studies, 4G/4G genotype or 4G allele may be a risk factor for development of disease,[121314] whereas others proposed a protective role for 4G/4G genotype or 4G allele against symptoms.…”

Section: Discussionmentioning

confidence: 99%

Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients

Shaghaghi

Bonyadi

Somi

et al. 2014

Saudi J Gastroenterol

View full text Add to dashboard Cite

Background/Aim:Previous studies have shown the association of some genetic factors, such as Plasminogen activator inhibitor type-1 (PAI-1) 4G/5G polymorphism, with the development of inflammatory bowel disease (IBD). We aimed to study this polymorphism as a risk factor in IBD patients in this cohort.Patients and Methods:One hundred and fifteen IBD patients and 95 healthy controls were selected from Iranian Azeri Turks and -6754G/5G polymorphism of PAI-1 gene was tested by polymerase chain reaction using allele-specific primers confirmed by sequencing.Results:There was no significant difference of PAI-1 polymorphism between IBD patients and the control group (P > 0.05). Furthermore, these data showed no significant difference between Crohn's disease and ulcerative colitis patients. However, 4G/4G homozygotes have reduced probability to progression of loss of appetite, whereas 5G/5G genotypes have increased risk for development of chronic diarrhea without blood, nausea, and loss of appetite.Conclusions:Although our study showed no significant association of PAI-1 polymorphism between patients and control group, the carriers of 4G/4G genotype and 4G allele had reduced risk for the progression of IBD features in this cohort.

show abstract

“…On the other hand, thromboxane A2 (TXA2) and thromboxane B2 (TXB2) have aggregating action, 36 as well as the inhibitor of plasminogen activator type 1 (PAI-1) that can promote the permanence of the fibrin clot inhibiting fibrinolysis. 38 Methylxanthines, such as caffeine, are non-selective blockers of the adenosine receptor 33 and act especially on the A2A receptor, specifically expressed in platelets. 33,39 Regarding platelet aggregation, in vitro studies indicate caffeine as a phosphodiesterase blocker, which blocks the conversion of cAMP into 5-AMP, increasing cAMP, with consequent inhibition of platelet aggregation.…”

Section: Introductionmentioning

confidence: 99%

Systematic Review of the Effects of Coffee or Its Components on Platelets and Their Regulators

Gache

Vaz

Almeida-de-Souza

2021

Journal of Caffeine and Adenosine Research

View full text Add to dashboard Cite

Background: Coffee includes some potentially bioactive components that can interfere with platelets, which can influence coagulation, despite generating controversy. The aim of this systematic review is to verify whether coffee or its components can influence platelet regulators and/or aggregation. Materials and Methods: The research was conducted on July 29, 2021, in PubMed, Scopus, and Web of Science, using the following mesh-terms: (caffeine)) OR (coffee)) AND (platelets). Eligibility criteria were: studies carried out in humans, referring to the effects of coffee consumption, or one of its components, on platelets or their regulators. We exclude in vitro or animal studies, reviews, editorials, and non-English written studies. From a total of 836 publications, 17 articles were included from which we extracted the relationship between coffee consumption and changes in blood platelets and performed a subjective assessment of bias. Results: Ten articles refer to the non-interference of coffee or its components with platelets, nine affirm results that support the increase in platelet aggregation, and eight articles observe the decrease in platelet aggregation when coffee is consumed. Some articles presented the lack of data regarding the sample collection location, age group, or classification as to the type of study, which is limiting. Conclusions: The heterogeneity of results makes it difficult to correctly interpret the possible interaction of coffee or its components with platelets or their regulators. For better interpretation, further studies on this topic should be carried out considering the individualization of coffee components, different platelet regulators, and the size of the sample used.

show abstract

Associação de níveis plasmáticos de PAI-1 e polimorfismo 4G/5G em pacientes com doença arterial coronariana

Abstract: Background: Type-1 plasminogen activator inhibitor (PAI-1) 4G/5G polymorphism may influence the PAI-1 expression. High plasma levels of PAI-1 are associated with coronary artery disease (CAD).

Cited by 15 publications

References 20 publications

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women

Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients

Systematic Review of the Effects of Coffee or Its Components on Platelets and Their Regulators

Contact Info

Product

Resources

About